Pages that link to "Q72296666"
Jump to navigation
Jump to search
The following pages link to Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus (Q72296666):
Displaying 50 items.
- Akt and mTOR in B Cell Activation and Differentiation (Q21131224) (← links)
- How I treat autoimmune lymphoproliferative syndrome (Q24633207) (← links)
- Metabolic regulation of T cell differentiation and function (Q26798088) (← links)
- Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus (Q26859557) (← links)
- Small molecules in the treatment of systemic lupus erythematosus (Q27010090) (← links)
- mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging (Q28081442) (← links)
- Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS) (Q28365993) (← links)
- Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. (Q33608479) (← links)
- Tuberous sclerosis and fulminant lupus in a young woman. (Q33664866) (← links)
- Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus (Q33664993) (← links)
- Pathogenic mechanisms in systemic lupus erythematosus. (Q33715441) (← links)
- Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome. (Q33715480) (← links)
- HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. (Q33717763) (← links)
- T-cell and B-cell signaling biomarkers and treatment targets in lupus (Q33718893) (← links)
- mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? (Q34107250) (← links)
- BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus (Q34245983) (← links)
- Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus (Q34361763) (← links)
- Chronic administration of dexamethasone results in Fc receptor up-regulation and inhibition of class I antigen expression on macrophages from MRL/lpr autoimmune mice (Q35230909) (← links)
- Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome (Q35732790) (← links)
- Nitric oxide, mitochondrial hyperpolarization, and T cell activation (Q35989081) (← links)
- N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial (Q36139749) (← links)
- Metabolic regulation of organelle homeostasis in lupus T cells (Q36177195) (← links)
- Sirolimus-associated proteinuria and renal dysfunction (Q36674174) (← links)
- Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. (Q36951816) (← links)
- Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway (Q37062514) (← links)
- Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study (Q37112911) (← links)
- Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis (Q37129534) (← links)
- Metabolic control of T cell activation and death in SLE. (Q37187126) (← links)
- Normalization of CD4 T cell metabolism reverses lupus (Q37625717) (← links)
- Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases (Q37649641) (← links)
- Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3. (Q37710586) (← links)
- CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance (Q37726675) (← links)
- Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells (Q37727280) (← links)
- Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases (Q37760379) (← links)
- Energy metabolism and rheumatic diseases: from cell to organism (Q38022768) (← links)
- Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. (Q38914374) (← links)
- Novel Treatments in Lupus (Q39164953) (← links)
- Biological therapy in systemic lupus erythematosus (Q42141973) (← links)
- Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection. (Q44326136) (← links)
- Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus (Q47574467) (← links)
- Disruption of the Gene Encoding the Mitogen-regulated Translational Modulator PHAS-I in Mice (Q52528321) (← links)
- Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. (Q52650139) (← links)
- Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. (Q55096330) (← links)
- Regulatory T cells in the treatment of disease (Q57471979) (← links)
- The Akt pathway in oncology therapy and beyond (Review) (Q58555910) (← links)
- Novel Treatments in Lupus (Q59798146) (← links)
- From Systemic Inflammation to Neuroinflammation: The Case of Neurolupus (Q59808939) (← links)
- Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus (Q61798742) (← links)
- Targeting Autophagy to Overcome Human Diseases (Q64226377) (← links)
- Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse (Q70865385) (← links)